Seroatlas · Human Serome Atlas

GLTPD2

Glycolipid transfer protein domain-containing protein 2

Also known as: GLTD2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: A6NH11
Gene: GLTPD2
Ensembl: ENSG00000182327
Chromosome: 17
Canonical length: 291 aa
Protein class: Predicted secreted proteins
Subcellular location: Nucleoplasm,Vesicles
Secretome location: Secreted - unknown location

OverviewNCBI Gene

Predicted to enable ceramide 1-phosphate binding activity and ceramide 1-phosphate transfer activity. Predicted to be involved in ceramide transport and intermembrane lipid transfer. Predicted to be located in cytoplasm. Predicted to be active in cytosol. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

291 residues, UniProt reviewed canonical sequence.

>A6NH11|GLTPD2
     1  MGVAARPPAL RHWFSHSIPL AIFALLLLYL SVRSLGARSG CGPRAQPCVP GETAPFQVRQ
    61  ESGTLEAPER KQPPCLGPRG MLGRMMRRFH ASLKPEGDVG LSPYLAGWRA LVEFLTPLGS
   121  VFAFATREAF TKVTDLEARV HGPDAEHYWS LVAMAAWERR AGLLEQPGAA PRDPTRSSGS
   181  RTLLLLHRAL RWSQLCLHRV ATGALGGPDA GVQCSDAYRA ALGPHHPWLV RQTARLAFLA
   241  FPGRRRLLEL ACPGATEAEA RAALVRAAGT LEDVYNRTQS LLAERGLLQL A

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GLTPD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 75 nTPM

Expression across tissuesHPA

Tissue

liver: 75 nTPM
kidney: 12 nTPM
duodenum: 9.5 nTPM
small intestine: 5.8 nTPM
cerebral cortex: 1.9 nTPM
skin: 1.6 nTPM

Single-cell type

hepatocytes: 169 nCPM
enterocytes: 56 nCPM
epicardial cells: 18 nCPM
epididymal efferent duct absorptive cells: 16 nCPM
gastric progenitor cells: 12 nCPM
neuroendocrine cells: 8.6 nCPM

Immune cell

non-classical monocyte: 0.6 nTPM
intermediate monocyte: 0.1 nTPM
myeloid DC: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM

Brain region

midbrain: 15 nTPM
medulla oblongata: 15 nTPM
cerebral cortex: 14 nTPM
cerebellum: 13 nTPM
pons: 13 nTPM
hypothalamus: 13 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.54
gnomAD pLI: 0
gnomAD missense Z: -0.16
DepMap mean gene effect: -0.06
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

cytosol

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Glycoprotein

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GLTPD2 as an antibody target. Whether an autoantibody or antibody against GLTPD2 could matter depends on whether native GLTPD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GLTPD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label GLTPD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...